ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2017; 8(4):674-682. doi:10.7150/jca.16901 This issue Cite
Review
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting
Department of Biomedical Sciences, Georgia-Philadelphia College of Osteopathic Medicine, Suwanee, GA 30024, USA.
Citation:
Wang JP, Hielscher A. Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. J Cancer 2017; 8(4):674-682. doi:10.7150/jca.16901. https://www.jcancer.org/v08p0674.htm
Other stylesAbstract
Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion, metastasis and therapy resistance. In particular, this review will focus on the interactions between cell receptor ligands and fibronectin and how this interaction influences downstream signaling events that aid tumor progression. This review will further discuss the possible implications of therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated that these studies will set a basis for future research that will not only aid understanding of fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics.
Keywords: Fibronectin, extracellular matrix, integrins, tumorigenesis, metastasis, therapy resistance.
Citation styles
APA
Wang, J.P., Hielscher, A. (2017). Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. Journal of Cancer, 8(4), 674-682. https://doi.org/10.7150/jca.16901.
ACS
Wang, J.P.; Hielscher, A. Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. J. Cancer 2017, 8 (4), 674-682. DOI: 10.7150/jca.16901.
NLM
Wang JP, Hielscher A. Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. J Cancer 2017; 8(4):674-682. doi:10.7150/jca.16901. https://www.jcancer.org/v08p0674.htm
CSE
Wang JP, Hielscher A. 2017. Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting. J Cancer. 8(4):674-682.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.